Francesco Blasi
(Italy)
Francesco Blasi
(Italy)
Francesco Blasi, MD, FERS is Professor of Respiratory Medicine in the Department of Pathophysiology and Transplantation at the University of Milan, Italy, as well as Head of Internal Medicine Department and Respiratory Unit of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. He is also director of the Adult Cystic Fibrosis Center of the Lombardia Regional Referral CF Center and currently a member of the Board of Directors of the University of Milan. From 2012–2013, he was president of European Respiratory Society (ERS) and from 2016–2017 president of the Italian Respiratory Society (SIP/IRS). From 2017–2018, he was president of the Italian Respiratory Society Research Center (SIP/IRS Centro Ricerche). Professor Blasi has published more than 350 papers in international journals (WEB of Science (01.12.2018) h-index : 50 Citations: 8620; SCOPUS (01.12.2018) : h-index:53 Citations:10680 ; Google Scholar (1.4.2019): h-index: 70, Citations: 17,668). His research interests include pneumonia, COPD, bronchiectasis, tuberculosis and NTM infections, cystic fibrosis and lung transplantation.
James D. Chalmers
(UK)
James D. Chalmers
(UK)
- Professor of Respiratory Research and Honorary Consultant Respiratory
- Physician at the University of Dundee/Ninewells Hospital, Dundee
- Chair of the European Bronchiectasis Network (EMBARC)
- Chair of the British Thoracic Society Science and Research Committee
- Chief Editor of the European Respiratory Journal
Sanjay Chotirmall
(Singapore)
Sanjay Chotirmall
(Singapore)
Sanjay H. Chotirmall A/Prof Chotirmall is an internationally recognized clinician-scientist with an established translational respiratory research group at the Lee Kong Chian School of Medicine, NTU Singapore. To date, he has performed key work on endo-phenotyping pulmonary infection, including the use of next generation sequencing approaches, in the context of chronic inflammatory respiratory diseases that have led to publications in Nature Medicine, the New England Journal of Medicine (NEJM), the Lancet Respiratory Medicine and the American Journal of Respiratory and Critical Care Medicine (AJRCCM). He has been appointed Provost’s Chair in Molecular Medicine at NTU Singapore since 2019 and leads "The Academic Respiratory Initiative for Pulmonary Health (TARIPH)", an interdisciplinary national academic initiative that aligns strategic academic expertise across Singapore to benefit Singaporeans with lung disease through research. He currently serves as Deputy Editor at the American Journal of Respiratory and Critical Care Medicine (AJRCCM).
Raja Dhar
(India)
Raja Dhar
(India)
MBBS(Cal), MD (Resp Med), MRCP (UK),
MSc (Evidence Based Medicine, UK),
CCT (Respiratory and General Medicine UK),
FCCP (USA), FICS (Indian Chest Society)
Diploma in Palliative Care (Newcastle University)
Certificate in Education (Teeside University) Director and Head of Dept, Pulmonology, C K group of Hospitals, Kolkata. Director Research and Education, National Allergy Asthma Bronchitis Institute, Kolkata. Chair- Training and Education Initiatives, Indian Chest Society ICS National Representative for the ERS Governing Body Member of the Indian Chest Society Director, First two HERMES exams Asia (European Diploma in Respiratory Medicine) Governing Body Member Indian Academy of Bronchology Joint Secretary Indian Academy of Allergy Founder Member South East Asian Academy of Sleep Medicine 124 International and National publications in indexed journals and Abstracts along with 17 Book Chapters. Associate Editor for Respirology and on Editorial Board for multiple other journals Dronocharya Award for Excellence in Continuing Medical Education in India (IHW) Coordinator for DNB course for the last 5 year. The first DNB Respiratory course in Bengal
Charles Feldman
(South Africa)
Charles Feldman
(South Africa)
Professor Charles Feldman was born and brought up in Johannesburg, South Africa. He obtained his MB BCh degree at the University of the Witwatersrand, in Johannesburg, in 1975 and served his internship at Johannesburg Hospital. He subsequently did his fellowship training in Internal Medicine at Johannesburg Hospital and received his FCP (SA) in 1981. He received his PhD in 1991 for a thesis entitled “Aspects of Community-acquired Pneumonia†and subsequently his DSc for a thesis also on the topic of CAP. He was registered as a sub-specialist in Pulmonology in 1993 and was elected to the Fellowship of the Royal College of Physicians (FRCP) in 1997.
From 1982 he worked as a consultant in the Division of Pulmonology/Critical Care in the Department of Medicine at Hillbrow Hospital in Johannesburg, and in 1986 became Director of the Intensive Care Unit and Pulmonology Unit of that Hospital. In May 1995 he was appointed as Professor of Pulmonology and Chief Physician, at Johannesburg Hospital and the University of the Witwatersrand, a position which he held until December 2017. He is currently an Emeritus Professor in the Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand.
In 1988/89 he was a Research Fellow and Honorary Senior Visiting Colleague, in the Host Defence Unit, Department of Thoracic Medicine, National Heart and Lung Institute, and Royal Brompton Hospital, London, United Kingdom.
Professor Feldman’s research interest is in the field of community-acquired pneumonia, and in particular pneumococcal pneumonia. In addition to being part of large international clinical collaborations recruiting cases of community-acquired pneumonia he has also contributed to basic research studies, investigating the effects of various pneumococcal virulence factors on human ciliated epithelium as well as investigating the effects of antibiotics on pneumococcal growth and expression of virulence factors. He has more than 380 publications in books, book chapters, and peer-reviewed journals. In 2018 he was awarded the Platinum Medical of the Medical Research Council of South Africa for a lifetime contribution to research in medical health in South Africa.
Claire Hogg
(UK)
Claire Hogg
(UK)
Claire Hogg is a Consultant at The Royal Brompton and Harefield Foundation Trust in London, UK. She is the clinical lead for the National Primary Ciliary Dyskinesia [PCD] Diagnostic service, in London.
The Royal Brompton is one of three National specialist centres for PCD in the UK where there are an estimated 3,000 patients. The Royal Brompton service cares for over 300 patients and sees around 400 referrals for diagnostics each year. This represents one of the largest PCD cohorts in Europe.
Alongside the clinical service, Claire runs an active research programme, focussing on chronic suppurative lung diseases, with a specific research and development programme aiming to bring advance PCD diagnostic tests into clinical practice. Foremost of these is the 3 dimensional electron tomography programme. Development of this technique has allowed for identification of previously unknown ultrastructural abnormalities in the axoneme of patients with novel mutations such as Hydin [pub 2012], dynein regulatory complex defects and those with DNAH11 mutations [pub 2017]. These genetic variations had no previously known ultrastructural defect as determined by conventional 2D electron tomography. It also has close collaborations with the geneticists at UCL, resulting in several novel gene discoveries. The group has also led on validating immunofluorescent Antibody staining techniques within the PCD diagnostic pathway [pub 2017], leading to a clinical roll out of this technique across the national Service.
Claire is UK lead for the first clinical trial in PCD as part of an EU programme grant [BESTcilia FP-7], Head of the BEAT-PCD training School [EU COST Action grant] and a member of the EU PCD Taskforce. Claire leads the PCD domain for the current Genomics UK project, tasked with improving genetic diagnosis for all patients with rare diseases.
Annemarie Lee
(Australia)
Annemarie Lee
(Australia)
Dr Annemarie Lee is an Associate Professor in Physiotherapy at Monash University. She co-developed the Bronchiectasis Toolbox and Strong Lungs websites, both providing resources for airway clearance techniques in people with bronchiectasis. Her current research areas include physiotherapy for bronchiectasis, examining the clinical impact of comorbidities in chronic respiratory conditions and adjuncts to pulmonary rehabilitation.
Pamela J. McShane
(USA)
Pamela J. McShane
(USA)
Dr. Pamela McShane started her journey attending medical school at Loyola University Stritch School of Medicine. From there, she became a recipient of the Health Professions Scholarship Program in the United States Air Force. Following her medical school and internal medicine residency training, Dr. McShane served as active duty in the U.S. Air Force at Wilford Hall Medical Center. She was stationed on Lackland Air Force base in San Antonio, Texas. While she was active duty, she was deployed twice to Iraq to support the freedom of Iraqi operations. Fulfilling her obligation, Dr. McShane returned to Chicago to finish her fellowship, where she continued her training in pulmonary and critical care medicine at the University of Chicago. Dr. McShane decided to stay at the University of Chicago, where she became a faculty member and directed the bronchiectasis and pulmonary nontuberculos mycobacteria clinical care center. During her time in the clinical care center, Dr. McShane accepted an offer specializing in the heart, lung, and blood at the Institution of National Institutes of Health in Bethesda, MD. At the National Institutes of Health, she focused on clinical care of pulmonary mycobacterium infections. Furthermore, she has been published extensively in the field of bronchiectasis. Through all her training, Dr McShane has found clinical patient to be the most rewarding aspect of her job. At this point in her life, Dr. McShane has found a home at the University of Texas Health Science Center and continually focuses on her love for clinical patient care. Dr. McShane has always been regarded as a doctor that cares and she takes pride in bringing that love to her patients every time they step through her office.
Kozo Morimoto
(Japan)
Kozo Morimoto
(Japan)
Kozo Morimoto, MD, Ph.D, is a pulmonologist at Fukujuji Hospital, Anti-Tuberculosis Association, Tokyo, where he serves as Chief of the Division of Clinical Research at the Respiratory Disease Center. He is also a professor in the Department of Clinical Mycobacteriosis at Nagasaki University Graduate School of Biomedical Science and a principal researcher at the Research Institute of Tuberculosis. Prof. Morimoto leads various projects within the division and department, focusing on the design and analysis of epidemiological and clinical studies of pulmonary diseases, particularly NTMPD and bronchiectasis.
Prof. Morimoto has published more than 100 articles in international peer-reviewed journals and contributed four book chapters on NTMPD. He is a board member of the Nontuberculous mycobacteriosis and bronchiectasis- Japan Research Consortium(JRC). Additionally, he is a member of the International Relations Committee of the Japanese Respiratory Society and the Nontuberculous Mycobacteriosis Control Committee of the Japanese Society for TB and NTM.
Jennifer Pollock
(UK)
Jennifer Pollock
(UK)
Jennifer Pollock is a PhD researcher within the Respiratory Research Group at the University of Dundee. She completed her MSci in Immunology at the University of Glasgow, before moving to Dundee to carry out her PhD which centres around characterising the eosinophilic endotype of bronchiectasis, with a particular interest in the therapeutic potential of currently licensed T2-modulating therapies for the management of this disease subset.
Bernadette Prentice
(Australia)
Bernadette Prentice
(Australia)
Dr Prentice has a Master’s of Public Health and a PhD in Cystic Fibrosis. Dr Prentice teaches medical students in her role as Conjoint Lecturer in The School of Women’s and Children’s Health at The University of New South Wales. Dr Prentice has been awarded both The Thoracic Society of New South Wales/ Vertex Paediatric Clinical fellowship award in 2016 and a National Health and Medical Research Council Scholarship to undertake her research in paediatric lung conditions. She has published articles in several peer reviewed journals on wet cough in children, asthma, cystic fibrosis and bronchiectasis. Dr Prentice has a special interest in bronchiectasis and equitable service delivery.
Steven Taylor
(Australia)
Steven Taylor
(Australia)
Steven leads the Respiratory Health Group within the Microbiome and Host Health Program. His research employs tailored techniques that allow the lung environment to be characterised to a high level of accuracy, including detailed measurements of airway microbiology (microbiome), mucus composition, and inflammation. This information is used to identify predictive markers of chronic lung disease severity as well as determine effective forms of therapy.
Basil Wicki
(Switzerland)
Basil Wicki
(Switzerland)
I am a PhD student at the Department of Biomedicine Basel, working in the research group of Dr. Lucas Boeck. Our primary objective is to identify bacterial mechanisms contributing to treatment failure, exploring their molecular underpinnings, and identifying potential targets for novel antimicrobial strategies, with a particular emphasis on Mycobacterium abscessus.
With a background in microbiology, I earned both my bachelor's and master's degrees from the University of Basel. During my master's studies, I conducted research at Bioversys AG, a Swiss pharmaceutical company, focusing on the role of transcriptional regulators as targets for anti-virulence compounds in Acinetobacter baumannii. Following my master's degree, I furthered my expertise at the Swiss Tropical and Public Health Institute, where I engaged in a civil service under the supervision of Prof. Sébastien Gagneux in the Tuberculosis Ecology and Evolution group, investigating resistance mechanisms in Mycobacterium tuberculosis.
Currently, my PhD project revolves around elucidating the landscape of drug interactions in Mycobacterium abscessus, aiming to uncover potential avenues for improved treatment strategies. Throughout my academic education, I have developed a keen interest in addressing the antimicrobial resistance crisis and the challenges posed by difficult-to-treat pathogens. It drives me to understand the underlying mechanisms and devise novel approaches to address the pressing challenges posed by antimicrobial resistance and the rise of treatment-resistant pathogens.
Jae-Joon Yim
(South Korea)
Jae-Joon Yim
(South Korea)
Dr. Jae-Joon Yim is a professor in the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea. He graduated from Seoul National University College of Medicine and was trained in Seoul National University Hospital as a resident and pulmonary fellow. From 2001 to 2002, he worked as a postdoctorial fellow in the laboratory of host defenses, NIAID, NIH, US, with the visiting fellowship award. Since 2002, he has been working as Assistant professor, Associate professor, and Professor in Seoul National University College of Medicine. He has been very active in terms of researches on various aspects of tuberculosis and non-tuberculous mycobacterial lung disease. After getting master’s degree on ‘Patient-Oriented research’ from Mailman’s School of Public Health, Columbia University in 2009, he has focused on clinical researches for tuberculosis and non-tuberculous mycobacterial lung disease. He is currently leading the Korean TB and NTM Research Group as the chairman.
Jin-fu Xu
(China)
Jin-fu Xu
(China)
Professor, Chief Physician, Department of Respiratory and Critical Care Medicine;
Vice President of Shanghai Pulmonary Hospital;
Head of Institute of Respiratory Medicine, School of Medicine, Tongji University, Shanghai
Standing member of Chinese Thoracic Society;
Elected Chairman of Shanghai Thoracic Society;
Founder and Executive Chairman of Bronchiectasis Registry China (BE-China)
Email: jfxucn@163.com; jfxu@tongji.edu.cn
Prof. Jin-fu Xu graduated and got his Medical Degree from Tongji Medical University (Wuhan), and got his PhD from Shanghai Medical College, Fudan University. He worked as a postdoctoral fellow at the Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Harvard Medical School in Boston.
Prof. Xu works as respiratory physician. His research is focusing on bronchiectasis, COPD and lung infections. He published over 100 articles in journals, including Nature Immunology, Lancet Digital Health, AJRCCM, European Respiratory Journal, EMBO molecular medicine, Chest, eBioMedicine, Clinical Microbiology and Infection, JEM, etc. He authored or was editor of 10 books.
Prof. Xu is the Founder and executive chairman of Bronchiectasis Registry China (BE-China) (http://www.chinabronchiectasis.com/), which is including more than 106 hospitals, the largest clinical study platform and the only one for bronchiectasis in China. He issued the Chinese Guideline of Diagnosis and Treatment of Bronchiectasis 2021. He is the Chief Editor of <Bronchiectasis> which is the first book of bronchiectasis in China. He is the Associate editor of Respiratory Research, and the Scientific editorial board member of Clinical Microbiology and Infection.
